Ubrogepant Works Quickly to Relieve Acute Migraine Pain
Ubrogepant, the newly approved calcitonin gene-related peptide antagonist, can relieve migraine symptoms within 2 hours after initial dose.
Migraine
The Association Between Different Subtypes of Major Depressive Disorder and Migraine
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
Discussion of Greater Occipital Nerve Block for Chronic Migraine
The authors refute a systematic review and meta-analysis of literature on greater occipital nerve block for the treatment of chronic migraine headaches by Shauly and colleagues and published in Plastic and Reconstructive Surgery, citing extensive limitations and claiming the study ultimately raises more questions than answers.
Biofeedback May Be Efficacious for Headache
Biofeedback may effectively improve headache and urinary incontinence related to prostatectomy.
FDA Expands GammaCore Device Clearance for Migraine-Associated Pain
The new approval for migraine patients was supported by the PRESTO trial, a multicenter, randomized, double-blind, sham-controlled trial.
Nasal Nerve Block Found to Treat Children with Migraines
Local anesthetic is administered to the sphenopalatine ganglion via nasal catheters.
